Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

RGS3 Is a GTPase-Activating Protein for Giα and Gqα and a Potent Inhibitor of Signaling by GTPase-Deficient Forms of Gqα and G11α

Astrid Scheschonka, Carmen W. Dessauer, Srikumar Sinnarajah, Peter Chidiac, Chong-Shan Shi and John H. Kehrl
Molecular Pharmacology October 2000, 58 (4) 719-728; DOI: https://doi.org/10.1124/mol.58.4.719
Astrid Scheschonka
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen W. Dessauer
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Srikumar Sinnarajah
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Chidiac
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chong-Shan Shi
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John H. Kehrl
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Many Regulators of G proteinSignaling (RGS) proteins accelerate the intrinsic GTPase activity of Giα and Gqα-subunits [i.e., behave as GTPase-activating proteins (GAPs)] and several act as Gqα-effector antagonists. RGS3, a structurally distinct RGS member with a unique N-terminal domain and a C-terminal RGS domain, and an N-terminally truncated version of RGS3 (RGS3CT) both stimulated the GTPase activity of Giα (except Gzα) and Gqα but not that of Gsα or G12α. RGS3 and RGS3CT had Gqα GAP activity similar to that of RGS4. RGS3 impaired signaling through Gq-linked receptors, although RGS3CT invariably inhibited better than did full-length RGS3. RGS3 potently inhibited GqαQ209L- and G11αQ209l-mediated activation of a cAMP-response element-binding protein reporter gene and GqαQ209L induced inositol phosphate production, suggesting that RGS3 efficiently blocks Gqα from activating its downstream effector phospholipase C-β. Whereas RGS2 and to a lesser extent RGS10 also inhibited signaling by these GTPase-deficient G proteins, other RGS proteins including RGS4 did not. Mutation of residues in RGS3 similar to those required for RGS4 Giα GAP activity, as well as several residues N terminal to its RGS domain impaired RGS3 function. A greater percentage of RGS3CT localized at the cell membrane than the full-length version, potentially explaining why RGS3CT blocked signaling better than did full-length RGS3. Thus, RGS3 can impair Gi- (but not Gz-) and Gq-mediated signaling in hematopoietic and other cell types by acting as a GAP for Giα and Gqα subfamily members and as a potent Gqα subfamily effector antagonist.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 58 (4)
Molecular Pharmacology
Vol. 58, Issue 4
1 Oct 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
RGS3 Is a GTPase-Activating Protein for Giα and Gqα and a Potent Inhibitor of Signaling by GTPase-Deficient Forms of Gqα and G11α
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

RGS3 Is a GTPase-Activating Protein for Giα and Gqα and a Potent Inhibitor of Signaling by GTPase-Deficient Forms of Gqα and G11α

Astrid Scheschonka, Carmen W. Dessauer, Srikumar Sinnarajah, Peter Chidiac, Chong-Shan Shi and John H. Kehrl
Molecular Pharmacology October 1, 2000, 58 (4) 719-728; DOI: https://doi.org/10.1124/mol.58.4.719

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

RGS3 Is a GTPase-Activating Protein for Giα and Gqα and a Potent Inhibitor of Signaling by GTPase-Deficient Forms of Gqα and G11α

Astrid Scheschonka, Carmen W. Dessauer, Srikumar Sinnarajah, Peter Chidiac, Chong-Shan Shi and John H. Kehrl
Molecular Pharmacology October 1, 2000, 58 (4) 719-728; DOI: https://doi.org/10.1124/mol.58.4.719
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics